Navigation Links
Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire/ -- Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML). Additionally, non-clinical data will be presented evaluating the effect of AC220 monotherapy and in combination with chemotherapy.

"AML continues to be a disease with a significant unmet medical need and new therapies are urgently needed," said M. Scott Salka, Chief Executive Officer of Ambit Biosciences. "The Phase I clinical data we've seen for AC220 in AML are extremely encouraging and supports the further development of this highly selective second-generation FLT3 inhibitor."

Data Highlights for AC220 include:

ORAL PRESENTATIONS

Abstract #636

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study

Presented by: Jorge Cortes, MD

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Date: Monday, December 7, 2009, 5:45pm (session: 4:30 - 6:00pm), Morial Convention Center Room 343-345

POSTER PRESENTATIONS

Abstract# 2053

AC220 - A FLT3 Inhibitor, Increases Survival in Two Genotypically Distinct FLT3-ITD Models of Acute Myeloid Leukemia and Provides Sustained Protection Following Chronic Administration

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Sunday, December 6, 2009, 6:00 - 8:00pm, Hall E, Poster Board II-45

Abstract#: 2052

AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Cell Culture and in Mouse Tumor Xenograft

Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation II

Sunday, December 6, 2009, 6:00 PM - 8:00 PM, Hall E, Poster Board II-44

About Acute Myeloid Leukemia (AML)

Acute myeloid leukemia is a form of blood cancer. According to the American Cancer Society, approximately 13,000 new cases of AML will be diagnosed in the United States in 2008. The median age of a patient with AML is about 67 years old. Standard treatment for patients 60 years or older with AML includes systemic combination chemotherapy. The median survival for patients receiving induction chemotherapy, which is associated with high mortality, is 6-11 months, with shorter survival for patients over the age of 60 years. The five-year survival rate for AML is less than 15 percent due to refractory and relapsed disease associated with standard treatments. According to a report from Decision Resources, the U.S. AML market is expected to more than double by 2015.

About Ambit Biosciences

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit employs a novel and proprietary kinase profiling technology named KINOMEscan(TM) to screen compounds against large numbers of human kinases. Ambit's lead compound, AC220, is in clinical development for the treatment of AML and other indications. Ambit plans to commence in 2009 several clinical studies with AC220, including a registration study in AML. Ambit's clinical pipeline also includes AC480, an oral panHER inhibitor that was in-licensed from BMS as part of an ongoing collaboration. Ambit is conducting Phase 2 studies with AC480 in patients with solid tumor cancers. Additionally, Ambit has an advancing pool of preclinical candidates targeting BRAF (in collaboration with Cephalon), JAK2, Aurora, and CSF1R. Through its KINOMEscan Division, Ambit markets its technology as a profiling service. For more information, visit www.ambitbio.com.


Contact:
--------
M. Scott Salka                            Scott Lerman
Ambit Biosciences                         The Ruth Group
(858) 334-2101                            (646) 536-7013
                                          slerman@theruthgroup.com

SOURCE Ambit Biosciences Corporation


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
3. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
4. Cell Biosciences Completes Acquisition of Alpha Innotech
5. Neurocrine Biosciences Reports Third Quarter 2009 Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
7. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
8. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
9. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
10. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
11. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/2/2016)... 2016 Kalorama Information noted the 5 Most ... in a recent white paper.  The healthcare market research ... a growing market are among the top drivers of ... EMR 2016: The Market for Electronic Medical ... study of the EMR industry, and the report is ...
(Date:5/2/2016)... 2016 The global  ultrasound ... billion by 2024, according to a new report ... of the sonography market include expanding applications of ... for periodic ultrasound screenings of the breast for ... ) High Intensity Focused Ultrasound ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City ... with a same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled ... performed her surgery the same day as her in-office consultation and eye exam. Francesca’s ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... multi-function small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL ... model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There is ... have plagued people since the beginning of recorded medical history, and in spite ... year. It's not just a matter of inconvenience; bladder infections cost us billions of ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... they acquired Pocono Sterilizer, an equipment sterilization service and sales company located in ... provides medical and research-related equipment and asset management services to the medical and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Vasont ... Vasont Universal Integrator (VUI) extension supports the latest release of Adobe FrameMaker, Release ... 2015 interlace the process of creating, editing and storing XML. , ...
Breaking Medicine News(10 mins):